AbbVie to Present New Dermatology Research at 2026 EADV Congress

AbbVie (NYSE: ABBV) announced it will present new research from its diverse dermatology portfolio at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, taking place from September 30 to October 3 in Vienna, Austria. The presentations will include 60 abstracts, with three late-breaking presentations, covering investigational compounds lutikizumab and zumilokibart, as well as approved therapies SKYRIZI® and RINVOQ®.